Unlabeled Anti-Cytokeratin 8, SB37b

Cat. No.
10080-01

Size
0.1 mg

Price (USD)
$185.00

Qty	Add to Cart

Technical Bulletin Certificate of
Analysis Safety Data Sheet Bulk/Custom
Quotation Request Email Technical
Service

Clone	SB37b
Isotype	Mouse (BALB/c) IgG_2aκ
Isotype Control	Mouse IgG_2a-UNLB
Immunogen	Recombinant C-terminal cytokeratin 8
Specificity	Cytokeratin 8
Alternalte Name(s)	CK 8, keratin 8
Description	Keratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I keratin (keratins 9 to 23) and one type II keratin (keratins 1-8). The two keratin types share only 30% sequence homology. Keratins demonstrate tissue- and differentiation-specific expression profiles. Cytokeratin 8 belongs to the type B (basic) subfamily of keratins and exists in combination with keratin 18. It is expressed in all simple type epithelia tissues (e.g., liver, pancreas, kidney, gut epithelial lining) but not in stratified squamous epithelia. Cytokeratin 8 is also present in the majority of adenocarcinomas and ductal carcinomas but is absent in most squamous cell carcinomas.
Format/Conjugate	UNLB (Unconjugated)
Buffer Formulation	Borate buffered saline, pH 8.2
Concentration	0.1 mg/mL
Volume	1.0 mL
Storage & Handling	2-8°C Please refer to product specific SDS
Applications	Applications for relevant formats of this clone include - Immunocytochemistry – Quality tested ¹ ELISA – Quality tested Immunohistochemistry-Paraffin Sections – Reported in literature ² Flow Cytometry ³ Western Blot ³ Immunoprecipitation ³
Recommended Dilutions	Please refer to product specific Technical Bulletin

Human pancreatic carcinoma cell line MIA PaCa-2 was stained with Mouse Anti-Cytokeratin 8-UNLB (SB Cat. No. 10080-01) followed by Goat Anti-Mouse IgG2a, Human ads-AP (SB Cat. No. 1080-04), Red AP, and mounted with Fluoromount-G® (SB Cat. No. 0100-01).
Human pancreatic carcinoma cell line MIA PaCa-2 was stained with Mouse Anti-Cytokeratin 8-UNLB (SB Cat. No. 10080-01; IgG2a) and Mouse Anti-Human MMP-1-UNLB (SB Cat. No. 12011-01; IgG2b) followed by Goat Anti-Mouse IgG2a, Human ads-AP (SB Cat. No. 1080-04) and Goat Anti-Mouse IgG2b, Human ads-HRP (SB Cat. No. 1090-05), Red AP, DAB, and mounted with Fluoromount-G® (SB Cat. No. 0100-01).

Human pancreatic carcinoma cell line MIA PaCa-2 was stained with Mouse Anti-Cytokeratin 8-UNLB (SB Cat. No. 10080-01) followed by Goat Anti-Mouse IgG2a, Human ads-AP (SB Cat. No. 1080-04), Red AP, and mounted with Fluoromount-G® (SB Cat. No. 0100-01).

Human pancreatic carcinoma cell line MIA PaCa-2 was stained with Mouse Anti-Cytokeratin 8-UNLB (SB Cat. No. 10080-01; IgG2a) and Mouse Anti-Human MMP-1-UNLB (SB Cat. No. 12011-01; IgG2b) followed by Goat Anti-Mouse IgG2a, Human ads-AP (SB Cat. No. 1080-04) and Goat Anti-Mouse IgG2b, Human ads-HRP (SB Cat. No. 1090-05), Red AP, DAB, and mounted with Fluoromount-G® (SB Cat. No. 0100-01).

References

1.	Chatin B, Mével M, Devallière J, Dallet L, Haudebourg T, Peuziat P, et al. Liposome-based formulation for intracellular delivery of functional proteins. Mol Ther Nucleic Acids. 2015;4:e244. (ICC)
2.	Wang D. Individualized cardiovascular medicine: identifying new mechanisms to inhibit the development of myointimal hyperplasia [dissertation]. Hamburg (Germany): University Medical Center Hamburg-Eppendorf; 2015. (IHC-PS)
3.	SouthernBiotech unpublished data (FC, WB, IP)

Back to Product List